Navigation Links
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Date:6/15/2010

FREISING-WEIHENSTEPHAN, Germany, June 15, 2010 /PRNewswire/ -- Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

"Meeting our goal of initiating this trial in the first half of 2010 demonstrates Pieris' commitment to establishing the safety and the therapeutic relevance of the Anticalin drug class," stated Stephen Yoder, CEO of Pieris. "Further, the high potency observed in preclinical studies, together with the small size and the lack of an antibody Fc domain, show promise of an attractive combined efficacy and safety profile for PRS-050."

The trial is designed to test PRS-050 in approximately 40 patients, who will receive the compound and then be monitored for safety and tolerability. The patients recruited for the trial are cancer patients with advanced, recurrent or metastatic solid tumors, refractory to standard therapy.

PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) Anticalin discovered and developed internally at the company from Pieris' proprietary Anticalin libraries. PRS-050's mechanism of action is based on its ability to bind the VEGF ligand, thereby inhibiting tumor growth. VEGF's role in cancer angiogenesis, the mechanism by which cancer tumors increase blood vessel development to deliver key nutrients and oxygen is well established, both scientifically and clinically.

About Pieris


'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
2. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
3. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
4. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
5. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... ALTO, Calif. , Jan. 22. 2015  Varian Medical Systems ... and software, has been honored for its commitment to sustainability ... sustainable companies. Varian is the highest ranked healthcare equipment company ... announced today during the World Economic Forum at ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... , Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval ... for the use of Medtronic,s SynchroMed ® II ... for use with United Therapeutics, Remodulin ® (treprostinil) ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... EDEN PRAIRIE, Minn., Oct. 7 ACIST Medical ... new 75,000 square foot,expanded corporate Headquarters and manufacturing ... Pawlenty and Eden Prairie Mayor Phil Young will,join ... for a ribbon cutting,ceremony at the company,s new ...
... Roche Diagnostics Makes List for Fourth Consecutive ... ranked Roche,Diagnostics as one of the magazine,s ... bestowed to only a handful of companies ... Diagnostics, which ranked No. 86, in the ...
... Oct. 7 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical Technology, Inc. ... and producer of plant extracts and pharmaceutical raw,materials ... in,Xi,an, China, is pleased to announce the signing ... Xintong Medical Ltd ("Qinba"). On,Sept 5, 2008 the ...
Cached Biology Technology:ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN 2ACIST Medical Systems Announces the Opening of Its New Expanded Corporate Headquarters in Eden Prairie, MN 3InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List 2Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of Qinba's Total Profit 2
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this market ... systems utilize more than one characteristic of an individual ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... of two marine turtles around the world,s oceans will be ... research project launched by the University of Exeter. ... nest in Gabon, Western Central Africa. The research team has ... enables the scientists to monitor their precise movements and observe ...
... N.J., Dec. 23 BIO-key International, Inc. (OTC Bulletin ... today announced the expansion of its biometric identity solutions ... Protocol (RDP), Citrix ICA Client platforms and for Wyse ... Application providers now have a simple solution to what ...
... and you will crash and burn; too slow and you may ... of images moving across their eyes. By slowing so that the ... constant, bees manage to control their approach. But what happens in ... adapt to landing on surfaces ranging from the horizontal to upside-down ...
Cached Biology News:Turtles' Christmas journey tracked by scientists 2BIO-key(R) Broadens Biometric Support for Microsoft(R) Windows Terminal Services, Citrix(R) Clients and Wyse CE Terminals 2BIO-key(R) Broadens Biometric Support for Microsoft(R) Windows Terminal Services, Citrix(R) Clients and Wyse CE Terminals 3BIO-key(R) Broadens Biometric Support for Microsoft(R) Windows Terminal Services, Citrix(R) Clients and Wyse CE Terminals 4Final moments of bee landing tactics revealed 2Final moments of bee landing tactics revealed 3
... with dishes and cell culture clusters. Linkage: ... number, created to easily match Cornings product ... order under the old Sigma-Aldrich number (Z71,334-1) ... Dim: blade L 1.9 cm handle L ...
... Protein A and Protein G bind ... immunoglobulins. Protein A and Protein G conjugates ... purify immunoglobulins (antibodies) and immunoglobulin subtypes from ... and other biological fluids. These reagents are ...
... Cell Identification Kit. ALDEFLUORs ... substrate for the enzyme ... is highly expressed in ... making ALDH an extremely ...
... at 470 nm; includes interface cable to S2000; ... into rack or desktop boxes The ... LED that produces either pulsed or continuous output ... for fluorescence measurements. The source is designed for ...
Biology Products: